QLS31901
- Generic Name
- QLS31901
A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies
- First Posted Date
- 2021-07-08
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT04954456
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath